Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vizamyl
18F-Flutemetamol, also known as Vizamyl, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to detect the presence of beta-amyloid plaques in the brain. These plaques are a hallmark of Alzheimer's disease and are associated with cognitive decline. The agent binds specifically to beta-amyloid, allowing for visualization and quantification of amyloid deposition. It aids in the evaluation of patients with cognitive impairment, helping to differentiate Alzheimer's disease from other forms of dementia.
Used in PET imaging to detect beta-amyloid plaques in the brain, aiding in the diagnosis of Alzheimer's disease.
Outcome:
Increased risk of radiation-related adverse effects.
Mechanism:
Cumulative radiation exposure
Outcome:
Potential alteration of amyloid binding properties.
Mechanism:
Competition for binding sites
Outcome:
No significant interactions have been identified.
Mechanism:
Unknown
Most likely new formulation: Improved radiotracers with higher sensitivity and specificity for amyloid detection (2025-2030, 70% confidence)
Based on increasing prevalence of Alzheimer's disease and the need for early diagnosis, demand for amyloid PET imaging agents like 18F-Flutemetamol is expected to grow steadily over the next decade.
Radiopharmaceutical, Diagnostic Agent
Benzothiazole